By Simon DyerBacteria are not homozygous in a mutation that causes their immune systems to become less aggressive, but scientists have discovered that they are genetically heterozygotes for a gene called RhoRhoB, which means they have two copies of the same gene.
This means that one of their two copies is always present, making them heterozygote.
It also means that they carry the mutated gene, which makes them more aggressive, even when their bodies don’t produce antibodies to the mutated protein.
This has been dubbed the “heterozygote mutation” and it is currently being studied in mice, but in humans it could be the key to treating or preventing other conditions.
It has also been found in the human body, so it could potentially help prevent or treat cancers.
The mutation has been found to affect both the production of a protein called RHoRho in the body and the production and function of the immune system, but the mechanism behind this mutation is still unknown.
The scientists at the University of Alberta and the University at Buffalo, New York, now report their findings in the journal Nature Communications.
“The ability to make antibodies against RhoB in the absence of antibodies is very promising, because it might be possible to develop treatments that target a different antigen,” said Professor Michael Buehler, from the Department of Molecular Biology at the university.
“We found that the heterozygose mutation makes RhoA less sensitive to antibody response and that RhoC becomes more responsive to antibody-mediated activation of the RhoG complex.”
RhoRHo is a member of a family of proteins that help defend the body against foreign invaders.
The Rho protein is known to cause antibodies to be produced, but there has been a lot of debate about how Rho can be used as a target for therapeutic or preventive therapies.
In the human immune system antibodies can be produced when Rho molecules attach to foreign proteins.
This allows the body to recognise and recognise foreign molecules, which are then attacked by antibodies.
This defence system works by targeting specific receptors in the immune cells, such as Rho proteins.
For this reason it is extremely important to protect our bodies from foreign substances, and it makes Rhi proteins very important for protecting against viruses.
The heterozygotic mutation is therefore very exciting because it may be able to help to develop therapies that target the RHO protein, and to prevent or prevent the production or activation of Rho by antibodies.
“Professor Buehl said that the RHo proteins are present in many cells in the adult human body and that they might be able be used to target and attack Rho.
This could be a powerful strategy for preventing or treating conditions like multiple sclerosis, Crohn’s disease, rheumatoid arthritis and diabetes, he said.”
I think this may be a very important discovery in the field of heterozygosity mutation in humans,” said Dr. J. Daniel Smith, from Harvard Medical School, who was not involved in the research.”
It opens up the possibility to use antibodies to target the immune systems of hetero- and heterozygosensitized individuals.
It could be that a vaccine that is delivered in heterozygoses would be more effective, but this would require targeting the RH1-RH3 gene.
“The research was funded by the National Institutes of Health._____